{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:04:14Z","timestamp":1790370254029,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003245","name":"Ministerie van Onderwijs, Cultuur en Wetenschap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymgme.2026.110256","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:07:41Z","timestamp":1788390461000},"page":"110256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug repurposing of glycerol phenylbutyrate for children with SLC6A1-related neurodevelopmental disorder: A prospective open-label case series"],"prefix":"10.1016","volume":"149","author":[{"given":"E.S.","family":"van Walree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.Z.","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Sprengers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Boussaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"van Muilekom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Alders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"van Haelst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Altinbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.B.","family":"Gunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Haaxma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.M.","family":"van der Vegt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.M.","family":"Grinspan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Schieving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.D.","family":"van Karnebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ymgme.2026.110256_bb0005","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa170","article-title":"Current knowledge of SLC6A1-related neurodevelopmental disorders","volume":"2","author":"Goodspeed","year":"2020","journal-title":"Brain Commun."},{"issue":"4","key":"10.1016\/j.ymgme.2026.110256_bb0010","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/brain\/awaa051","article-title":"A catalogue of new incidence estimates of monogenic neurodevelopmental disorders caused by de novo variants","volume":"143","author":"L\u00f3pez-Rivera","year":"2020","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.ymgme.2026.110256_bb0015","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ajhg.2024.04.021","article-title":"Haploinsufficiency underlies the neurodevelopmental consequences of SLC6A1 variants","volume":"111","author":"Silva","year":"2024","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110256_bb0020","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1476-5381.2012.01975.x","article-title":"The solute carrier 6 family of transporters","volume":"167","author":"Br\u00f6er","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110256_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac144","article-title":"4-Phenylbutyrate restored \u03b3-aminobutyric acid uptake and reduced seizures in SLC6A1 patient variant-bearing cell and mouse models","volume":"4","author":"Nwosu","year":"2022","journal-title":"Brain Commun."},{"key":"10.1016\/j.ymgme.2026.110256_bb0030","article-title":"A draft conceptual model of SLC6A1 neurodevelopmental disorder","volume":"16","author":"Goodspeed","year":"2022","journal-title":"Front. Neurosci."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110256_bb0035","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/17446651.2014.945908","article-title":"Glycerol phenylbutyrate for the chronic management of urea cycle disorders","volume":"9","author":"Oishi","year":"2014","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2026.110256_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2025.107621","article-title":"Phenylbutyrate for monogenetic epilepsy: literature review","volume":"217","author":"Stone","year":"2025","journal-title":"Epilepsy Res."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110256_bb0045","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/hep.26611","article-title":"Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy","volume":"59","author":"Rockey","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ymgme.2026.110256_bb0050","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1097\/MPG.0000000000002713","article-title":"Glycerol phenylbutyrate therapy in progressive familial intrahepatic cholestasis type 2","volume":"70","author":"Almes","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"10","key":"10.1016\/j.ymgme.2026.110256_bb0055","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1210\/clinem\/dgae146","article-title":"Glycerol phenylbutyrate treatment of 2 patients with monocarboxylate transporter 8 deficiency","volume":"109","author":"Zung","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2026.110256_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2025.107708","article-title":"4-Phenylbutyrate rescues neurobehavioral phenotypes in SLC6A1-related encephalopathy","volume":"220","author":"Randhave","year":"2026","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ymgme.2026.110256_bb0065","first-page":"1","article-title":"4-Phenylbutyrate for STXBP1 and SLC6A1. Safety, tolerability, seizure, and EEG outcomes","author":"Grinspan","year":"2024","journal-title":"A case series at 2 centers, medRxiv 24316676"},{"key":"10.1016\/j.ymgme.2026.110256_bb0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pediatrneurol.2026.06.012","article-title":"Parent-reported improvement in seizure control and development after Phenylbutyrate treatment in children with STXBP1 and SLC6A1","volume":"182","author":"Barbour","year":"2026","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymgme.2026.110256_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2025.107514","article-title":"4-Phenylbutyrate restored GABA uptake, mitigated seizures in SLC6A1 and SLC6A11 microdeletions\/3p- syndrome: from cellular models to human patients","volume":"210","author":"DeLeeuw","year":"2025","journal-title":"Epilepsy Res."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110256_bb0085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12874-019-0866-x","article-title":"Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation","volume":"19","author":"Gaasterland","year":"2019","journal-title":"BMC Med. Res. Methodol."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110256_bb0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12888-023-05422-3","article-title":"Cannabidiol (Epidyolex\u00ae) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials","volume":"24","author":"M\u00fcller","year":"2024","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.ymgme.2026.110256_bb0095","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s13023-021-02003-z","article-title":"Methylphenidate for attention-deficit\/hyperactivity disorder in patients with Smith-Magenis syndrome: protocol for a series of N-of-1 trials","volume":"16","author":"M\u00fcller","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110256_bb0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.25498","article-title":"The effect of intrathecal baclofen in Dyskinetic cerebral palsy: the IDYS trial","volume":"86","author":"Bonouvri\u00e9","year":"2019","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.ymgme.2026.110256_bb0105","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1080\/09638288.2022.2057600","article-title":"Attainment of personal goals in the first year of intrathecal baclofen treatment in dyskinetic cerebral palsy: a prospective cohort study","volume":"45","author":"Bonouvri\u00e9","year":"2023","journal-title":"Disabil. Rehabil."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110256_bb0110","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12311-023-01543-3","article-title":"Scale for the assessment and rating of Ataxia (SARA): development of a training tool and certification program","volume":"23","author":"Grobe-Einsler","year":"2024","journal-title":"Cerebellum"},{"issue":"2","key":"10.1016\/j.ymgme.2026.110256_bb0115","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/1073191115577189","article-title":"Accuracy of short forms of the Dutch Wechsler preschool and primary scale of intelligence: third edition","volume":"23","author":"Hurks","year":"2016","journal-title":"Assessment"},{"issue":"1","key":"10.1016\/j.ymgme.2026.110256_bb0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12474-019-00241-3","article-title":"WISC-V-NL","volume":"24","author":"Rosbach","year":"2020","journal-title":"Neuropraxis"},{"key":"10.1016\/j.ymgme.2026.110256_bb0125","series-title":"Bayley Scales of Infant and Toddler Development, Third Edition (Bayley--III\u00ae)","author":"Bayley","year":"2005"},{"issue":"2","key":"10.1016\/j.ymgme.2026.110256_bb0130","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/mpr.282","article-title":"Vineland screener 0-12 years research version (NL). Constructing a screening instrument to assess adaptive behaviour","volume":"18","author":"van Duijn","year":"2009","journal-title":"Int. J. Methods Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110256_bb0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1073191114533814","article-title":"The brief irritability test (BITe): a measure of irritability for use among men and women","volume":"22","author":"Holtzman","year":"2015","journal-title":"Assessment"},{"issue":"8","key":"10.1016\/j.ymgme.2026.110256_bb0140","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","article-title":"PedsQL 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations","volume":"39","author":"Varni","year":"2001","journal-title":"Med. Care"},{"issue":"8","key":"10.1016\/j.ymgme.2026.110256_bb0145","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1023\/A:1008981603178","article-title":"Development and psychometric evaluation of the TAPQOL: a health-related quality of life instrument for 1-5-year-old children","volume":"9","author":"Fekkes","year":"2000","journal-title":"Qual. Life Res."},{"issue":"7","key":"10.1016\/j.ymgme.2026.110256_bb0150","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s11136-010-9836-9","article-title":"Fatigue in children: reliability and validity of the Dutch PedsQL\u2122 multidimensional fatigue scale","volume":"20","author":"Gordijn","year":"2011","journal-title":"Qual. Life Res."},{"issue":"9","key":"10.1016\/j.ymgme.2026.110256_bb0155","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1007\/s11136-013-0370-4","article-title":"Factorial invariance of pediatric patient self-reported fatigue across age and gender: a multigroup confirmatory factor analysis approach utilizing the PedsQL\u2122 multidimensional fatigue scale","volume":"22","author":"Varni","year":"2013","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ymgme.2026.110256_bb0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1471-2431-9-68","article-title":"Health related quality of life of Dutch children: psychometric properties of the PedsQL in the Netherlands","volume":"9","author":"Engelen","year":"2009","journal-title":"BMC Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110256_bb0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12955-017-0654-4","article-title":"Health related quality of life in Dutch infants, toddlers, and young children","volume":"15","author":"Schepers","year":"2017","journal-title":"Health Qual. Life Outcomes"},{"issue":"3","key":"10.1016\/j.ymgme.2026.110256_bb0170","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-0036-1584357","article-title":"The psychosocial impact of Fabry disease on pediatric patients","volume":"5","author":"Bugescu","year":"2016","journal-title":"J. Pediatr. Genet."},{"key":"10.1016\/j.ymgme.2026.110256_bb0175","series-title":"R: A Language and Environment for Statistical Computing","author":"Team RC","year":"2023"},{"key":"10.1016\/j.ymgme.2026.110256_bb0180","series-title":"IBM SPSS Statistics for Windows","year":"2022"},{"issue":"5","key":"10.1016\/j.ymgme.2026.110256_bb0190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110256_bb0195","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/epi.13986","article-title":"Defining the phenotypic spectrum of SLC6A1 mutations","volume":"59","author":"Johannesen","year":"2018","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ymgme.2026.110256_bb0200","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/epi.14618","article-title":"Diagnostic exome sequencing in 100 consecutive patients with both epilepsy and intellectual disability","volume":"60","author":"Snoeijen-Schouwenaars","year":"2019","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.ymgme.2026.110256_bb0205","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/jmedgenet-2021-107694","article-title":"Neurodevelopmental phenotypes associated with pathogenic variants in SLC6A1","volume":"59","author":"Kahen","year":"2022","journal-title":"J. Med. Genet."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110256_bb0210","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1093\/brain\/awad292","article-title":"SLC6A1 variant pathogenicity, molecular function and phenotype: a genetic and clinical analysis","volume":"146","author":"Stefanski","year":"2023","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ymgme.2026.110256_bb0215","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ajhg.2015.02.016","article-title":"Mutations in the GABA transporter SLC6A1 cause epilepsy with myoclonic-atonic seizures","volume":"96","author":"Carvill","year":"2015","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110256_bb0220","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13041-020-00612-6","article-title":"Endoplasmic reticulum retention and degradation of a mutation in SLC6A1 associated with epilepsy and autism","volume":"13","author":"Wang","year":"2020","journal-title":"Mol. Brain"},{"issue":"8","key":"10.1016\/j.ymgme.2026.110256_bb0225","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/brain\/awab207","article-title":"Common molecular mechanisms of SLC6A1 variant-mediated neurodevelopmental disorders in astrocytes and neurons","volume":"144","author":"Mermer","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2026.110256_bb0230","article-title":"Drosophila melanogaster as a model for unraveling unique molecular features of epilepsy elicited by human GABA transporter 1 variants","volume":"16","author":"Kasture","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ymgme.2026.110256_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110658","article-title":"The roles of ER stress in epilepsy: molecular mechanisms and therapeutic implications","volume":"131","author":"Fu","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110256_bb0240","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1194\/jlr.M900216-JLR200","article-title":"The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response","volume":"50","author":"Basseri","year":"2009","journal-title":"J. Lipid Res."},{"issue":"17","key":"10.1016\/j.ymgme.2026.110256_bb0245","doi-asserted-by":"crossref","first-page":"14941","DOI":"10.1074\/jbc.M110.211029","article-title":"Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease","volume":"286","author":"Zhou","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110256_bb0250","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/s41467-024-46391-9","article-title":"DJ-1 protects proteins from acylation by catalyzing the hydrolysis of highly reactive cyclic 3-phosphoglyceric anhydride","volume":"15","author":"Akhmadi","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110256_bb0255","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.ejhg.5201320","article-title":"Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients","volume":"13","author":"Brahe","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110256_bb0260","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1471-4159.2005.03077.x","article-title":"Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice","volume":"93","author":"Ryu","year":"2005","journal-title":"J. Neurochem."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110256_bb0265","doi-asserted-by":"crossref","first-page":"8299","DOI":"10.1074\/jbc.M112.426536","article-title":"Sodium phenylbutyrate enhances astrocytic neurotrophin synthesis via protein kinase C (PKC)-mediated activation of cAMP-response element-binding protein (CREB): implications for Alzheimer disease therapy","volume":"288","author":"Corbett","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110256_bb0270","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41687-024-00716-w","article-title":"A systematic review of goal attainment scaling implementation practices by caregivers in randomized controlled trials","volume":"8","author":"Cheema","year":"2024","journal-title":"J. Patient Rep. Outcomes."},{"issue":"5 Suppl 1","key":"10.1016\/j.ymgme.2026.110256_bb0275","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","article-title":"The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years","volume":"45","author":"Cella","year":"2007","journal-title":"Med. Care"},{"issue":"1","key":"10.1016\/j.ymgme.2026.110256_bb0280","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s11689-025-09647-z","article-title":"Patient reported outcomes that matter to individuals with (genetic) intellectual disabilities: a qualitative study","volume":"17","author":"van Silfhout","year":"2025","journal-title":"J. Neurodev. Disord."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110256_bb0285","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.outlook.2014.05.009","article-title":"Patient-reported outcomes measurement information system (PROMIS): efficient, standardized tools to measure self-reported health and quality of life","volume":"62","author":"Bevans","year":"2014","journal-title":"Nurs. Outlook"},{"key":"10.1016\/j.ymgme.2026.110256_bb0290","unstructured":"Van Silfhout N.Y.; van Muilekom M.M.; Menke L.A.; van Karnebeek C.D.; Kleinendorst L.; Boot E.; Luijten M.A.J.; Haverman L.; van Eeghen A.M., Toward a core patient reported outcome measure (PROM) set for (genetic) intellectual disabilities: evaluating reliability, efficiency, and validity. [Manuscript submitted for publication]."},{"issue":"16","key":"10.1016\/j.ymgme.2026.110256_bb0295","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1080\/09638280802572973","article-title":"The ICF-CY and goal attainment scaling: benefits of their combined use for pediatric practice","volume":"31","author":"McDougall","year":"2009","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.ymgme.2026.110256_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2023.101233","article-title":"Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation: rationale and protocol for single patient (n-of-1) multiple cross-over trials","volume":"36","author":"den Hollander","year":"2023","journal-title":"Contemp. Clin. Trials Commun."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226005391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226005391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:35:34Z","timestamp":1790368534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226005391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1096719226005391"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110256","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing of glycerol phenylbutyrate for children with SLC6A1-related neurodevelopmental disorder: A prospective open-label case series","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110256"}}